InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a report issued on Monday. The firm set a “sell” rating on the stock.

Separately, Piper Sandler reiterated an “overweight” rating and set a $4.50 price objective on shares of InspireMD in a report on Tuesday, September 17th.

InspireMD Stock Performance

Shares of NYSE NSPR opened at $2.57 on Monday. InspireMD has a fifty-two week low of $1.81 and a fifty-two week high of $3.42. The company has a market cap of $67.03 million, a price-to-earnings ratio of -3.43 and a beta of 0.93. The business’s 50 day moving average price is $2.57 and its 200-day moving average price is $2.61.

InspireMD (NYSE:NSPR) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. The business had revenue of $1.81 million for the quarter, compared to analyst estimates of $1.74 million. During the same quarter last year, the firm posted ($0.15) earnings per share. Sell-side analysts predict that InspireMD will post -0.79 earnings per share for the current year.

Institutional Trading of InspireMD

Hedge funds have recently added to or reduced their stakes in the business. Parkman Healthcare Partners LLC bought a new stake in shares of InspireMD in the 3rd quarter valued at about $279,000. Affiance Financial LLC purchased a new position in InspireMD during the third quarter valued at approximately $492,000. Finally, Rosalind Advisors Inc. raised its stake in InspireMD by 266.4% in the second quarter. Rosalind Advisors Inc. now owns 2,513,641 shares of the company’s stock worth $6,272,000 after buying an additional 1,827,579 shares in the last quarter. 44.78% of the stock is owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.